Table 2 Distribution of the studies according to each possible methodological choice
Category | Nalmefene (n = 9) | Naltrexone (n = 51) |
|---|---|---|
Medical condition | ||
AD only | 6 (66.7%) | 33 (64.7%) |
AUDs | 3 (33.3%) | 18 (35.3%) |
Abstinence | ||
< 5 days | 9 (100%) | 34 (66.7%) |
≥ 5 days | 0 (0.0%) | 17 (33.3%) |
Gender | ||
Mixed | 9 (100%) | 39 (76.5%) |
Males or females only | 0 (0.0%) | 12 (23.5%) |
Systematic somatic comorbidity | ||
No | 9 (100%) | 48 (94.1%) |
Yes | 0 (0.0%) | 3 (5.9%) |
Systematic psychiatric comorbidity | ||
No | 9 (100%) | 39 (76.4%) |
Yes | 0 (0.0%) | 12 (23.5%) |
Psychological support | ||
No | 1 (11.1%) | 4 (7.8%) |
Yes | 8 (88.9%) | 47 (92.2%) |
Treatment and dose | ||
Approved dose and route of administration | ||
No | 6 (66.7%) | 14 (27.5%) |
Yes | 3 (33.3%) | 37 (72.5%) |
Maximum dose tested | ||
No | 8 (88.9%) | 50 (98.0%) |
Yes | 1 (11.1%) | 1 (2.0%) |
Treatment duration | ||
≥ 12 weeks | 9 (100%) | 41 (80.4%) |
< 12 weeks | 0 (0.0%) | 10 (19.6%) |
Outcome reported | ||
Quantity of alcohol consumed | ||
No | 0 (0.0%) | 21 (41.2%) |
Yes | 9 (100%) | 30 (58.8%) |
Frequency of drinking | ||
No | 2 (22.2%) | 16 (31.4%) |
Yes | 7 (77.8%) | 35 (68.6%) |
Abstinence | ||
No | 0 (0.0%) | 18 (35.3%) |
Yes | 9 (100%) | 33 (64.7%) |
Publication | ||
Published | 7 (77.8%) | 48 (94.1%) |
Unpublished | 2 (22.2%) | 3 (5.9%) |
Risk of bias | ||
High risk of selective outcome reporting | 2 (22.2%) | 5 (9.8%) |
Unclear or low risk of selective outcome reporting | 7 (77.8%) | 46 (90.2%) |